Psoriasis - Identifying and Commercializing First-in-Class Innovation Market Research Report: Radiant Insights, Inc

Other agents which activate regulatory arms of the immune system have also shown
promising clinical profiles. In addition, innovative programs that target molecules have
only recently gained recognition of their therapeutic value in the treatment of psoriasis,
including novel angiogenic proteins, signaling transduction proteins and novel nuclear
receptors. Despite their recent implication in disease pathophysiology, many of these
agents have also demonstrated clinical utility in the treatment of psoriasis and are likely to
contribute to a diversified therapeutic landscape.
Scope
- A brief introduction to psoriasis, including symptoms, pathophysiology, and overview of
pharmacotherapy
- The changing molecular target landscape between market and pipeline and particular
focal points of innovation
Read Complete Report with TOC @ http://www.radiantinsights.com/research/frontierpharma-psoriasis-identifying-and-commercializing-first-in-class-innovation
- Overview of how innovative products are contributing to the pipeline and market for
psoriasis
- Comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of
phase distribution, molecule type, molecular target, and administration route
- Identification and assessment of first-in-class molecular targets with a particular focus on
early-stage programs of which clinical utility has yet to be evaluated, as well as literature
reviews on novel molecular targets
- Assessment of the licensing and co-development deals for psoriasis therapies
Reasons to buy
- Understanding of the focal shifts in molecular targets in the psoriasis pipeline
- Understanding of the distribution of pipeline programs by phase of development,
molecule type and molecular target
- Scientific and clinical analysis of first-in-class developmental programs
- Assessment of the valuations of licensed and co-developed psoriasis treatments
- A list of the first-in-class therapies potentially open to deal-making opportunities.
- Analysis of financial valuations on licensed or co-developed first-in-class therapies and
generics